InSilicoMinds is featured in the Avicenna Alliance Newsletter for March/April 2026. The AI Task Force Spotlight, written by our Founder and CEO Nirnith Devireddy as Co-Chair of the Avicenna Alliance AI Task Force, tackles a central question: how do we turn AI innovation into regulatory-grade evidence?
AI has shown monumental performance gains in the past few years. The real challenge lies in whether it can be trusted, explained, validated, and accepted by regulators and healthcare stakeholders. Our piece explores how the AI Task Force is working to bridge traditional Computational Modelling & Simulation with emerging AI-driven technologies, and why that combination matters more than either approach alone.
A few things worth highlighting from the article:
• AI currently dominates headlines, but its success in pharma relies heavily on the scientific and mechanistic foundations built through decades of computational modelling and simulation.
• The regulatory shift is clear: explainability, transparency, context-of-use validation, and human oversight are becoming non-negotiable.
• A recent FDA warning letter to a cosmetics lab that relied on AI-generated documentation without sufficient human oversight is a reminder that AI cannot replace scientific expertise or regulatory accountability.
• Responsible AI implementation is not optional; it is central to patient safety and regulatory confidence.
This is something we think about every day at InSilicoMinds: AI and Computational Modelling & Simulation working together, not AI replacing the science but amplifying it. The future of healthcare and life sciences AI will not be defined by capability alone. It will be defined by credibility.
The full piece appears in the Avicenna Alliance Newsletter, March/April 2026.
https://www.avicenna-alliance.com/upload/avicenna-alliance-newsletter-march-april-2026_6a228a4ca3100.pdf
